UnknownPhase 3

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Mexico72 participantsStarted 2020-03-30

Plain-language summary

To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity. It is known that SGLT2 inhibitors develop cardiac protection over long term administration, but there's not enough studies about acute effects in early administration.

Who can participate

Age range40 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of T2DM * HbA1c \> 7 y \< 10 * BMI 25 - 34.9 kg/m2 * Signature of consent under information Exclusion Criteria: * Hypertension * Treated with insulin and / or loop diuretics and thiazides * T1DM * Hypotension * Any autoimmune disease * Liver disease * Women whitout birth control method * Women taking oral birth control or under hormone replacement therapy * Woman pregnant or breastfeeding * Untreated thyroid disease * Patients with a cardiovascular disease that contraindicates the use of this pharmacological class * Glomerular filtration rate \<60ml/min (Cockcroft-Gault)

What they're measuring

Pulse wave velocity

Timeframe: 7 days

Trial details

NCT IDNCT05109949

SponsorCentro Universitario de Ciencias de la Salud, Mexico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-06-01

View on ClinicalTrials.gov More Diabetes Mellitus Type 2 Without Complication trials